US-based medical device company QT Imaging Holdings Inc (OTCQB: QTIH) revealed on Monday that it has entered into an exclusive distribution agreement with Gulf Medical Co for the supply of its FDA-cleared Breast Acoustic CT scanner and subscriptions to the QTI Cloud Platform in Saudi Arabia.
The agreement sets minimum orders of five scanners per quarter beginning in the first quarter of 2026 through to the end of 2028, totalling at least 60 scanners and generating revenue of more than USD33m. Gulf Medical will also distribute QTI's AI-enabled cloud platform, designed to enhance breast health imaging through automated classification and second-read decision support.
QTI's non-invasive 3D breast imaging technology, which avoids compression, contrast agents and radiation, is particularly relevant in Saudi Arabia where genetic predispositions, including BRCA1 and BRCA2 mutations, contribute to higher breast cancer incidence among women aged 40 to 59.
Founded in 1983, Gulf Medical Co, part of the Al-Naghi Group, is a leading distributor of medical technologies across the Middle East.
QT Imaging Holdings is a US-based medical device company focused on safe, affordable and patient-centered imaging systems using low-frequency sound waves.
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Lupin launches Dasatinib tablets in US market
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA
FDA approves Tenpoint Therapeutics' YUVEZZI as first dual-agent eye drop for presbyopia
Summit Therapeutics' BLA for ivonescimab in EGFR-mutated NSCLC accepted by FDA
WuXi Biologics collaborates with Sinorda Biomedicine for antibody development
Biogen's litifilimab receives FDA Breakthrough Therapy Designation for CLE
Glaukos receives FDA approval for repeat administration of iDose TR
Guerbet's contrast agent Elucirem approved by European Commission in children from birth
Spine Innovation's LOGIC Titanium Implant System receives US FDA 510(k) market approval